Tarsus Pharmaceuticals Financials - Benzinga

Tarsus Pharmaceuticals Inc

TARSNASDAQ

Trade with Public

Trade with Public

$82.76

8.7111.76%

At close: Sep 2, 5:00 PM EST

$82.00

-0.76-0.92%

After Hours: 6:16 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Tarsus Pharmaceuticals Financials

Tarsus Pharmaceuticals (TARS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Tarsus Pharmaceuticals Q2 EPS $(0.43) Misses $(0.20) Estimate, Sales $173.912M Beat $169.677M Estimate

Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.20) by 115 percent. This is a 10.42 percent increase over losses of $(0.48) per

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Tarsus Pharmaceuticals Reaffirmed Full-year 2026 Guidance Of $670M-700M Of Xdemvy Net Product Sales And Peak Sales Potential Exceeding $2B

Benzinga Newsdesk

PRO
Tarsus Pharmaceuticals Q1 EPS $(0.16) Beats $(0.33) Estimate, Sales $162.054M Beat $148.422M Estimate

Benzinga Newsdesk

PRO
Tarsus Pharmaceuticals Q4 EPS $(0.20) Misses $(0.11) Estimate, Sales $151.668M Beat $144.565M Estimate

Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.11) by 81.82 percent. This is a 66.67 percent increase over losses of $(0.60) per

Benzinga Newsdesk

Insights into Tarsus Pharmaceuticals Q4 Earnings

Benzinga Insights